Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

Br J Haematol. 2020 Jul;190(2):e83-e86. doi: 10.1111/bjh.16874. Epub 2020 Jun 10.

¹ Leeds Institute of Clinical Trial Research & Leeds Cancer Centre, University of Leeds, Leeds, UK.
² Department of Haematology, Pinderfields Hospital, Mid Yorkshire NHS Trust, Wakefield, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁴ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
⁵ NIHR BRC Blood Theme, Oxford University Hospitals NHS FT, Oxford, UK.
⁶ The Institute of Cancer Research, London, UK.
⁷ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
⁸ Department of Haematology, Nottingham City Hospital, Nottingham, UK.
⁹ The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.
¹⁰ Department of Haematology, Epsom & St Helier University Hospitals NHS Trust, Carshalton, UK.
¹¹ Department of Haematology, Guys and St Thomas's Trust, London, UK.
¹² Department of Haematology, University Hospital of Wales, Cardiff, UK.
¹³ The Beatson West of Scotland Cancer Centre, Glasgow, UK.
¹⁴ Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.

No abstract available

Keywords: COVID-19; multiple myeloma; systemic antic-cancer therapy.

Publication types